OTSUKA PAKISTAN LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.7 PKR | +0.52% |
|
-1.79% | -7.25% |
| 02-29 | Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
| 02-28 | Otsuka Pakistan Limited Announces Board Changes | CI |
| Sales 2022 | 2.85B 10.25M 818M | Sales 2023 | 3.04B 10.91M 870M | Capitalization | 876M 3.15M 251M |
|---|---|---|---|---|---|
| Net income 2022 | 232M 834K 66.51M | Net income 2023 | -7M -25.16K -2.01M | EV / Sales 2022 | 1.19 x |
| Net Debt 2022 | 447M 1.61M 128M | Net Debt 2023 | 937M 3.37M 269M | EV / Sales 2023 | 0.6 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
-122
x | Employees | 362 |
| Yield 2022 |
0.62% | Yield 2023 |
2.07% | Free-Float | 38.77% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.52% | ||
| 1 week | -1.79% | ||
| Current month | +0.38% | ||
| 1 month | -2.63% | ||
| 3 months | -5.34% | ||
| 6 months | +26.57% | ||
| Current year | -7.25% |
1 week
126.51
132.00
1 month
124.37155.00
Current year
121.00172.85
1 year
68.50185.89
3 years
68.50330.00
5 years
68.50421.00
10 years
41.05421.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sajid Ali Khan
DFI | Director of Finance/CFO | - | 04/03/12 |
David Sunil
ADM | Chief Administrative Officer | - | - |
| Director/Board Member | - | 31/12/96 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abid Hussain
BRD | Director/Board Member | - | - |
| Director/Board Member | - | 31/12/96 | |
Suhari Mukti
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 129.7 | +0.52% | 13,085 |
| 03/05/24 | 129 | +1.42% | 8,913 |
| 02/05/24 | 127.2 | -1.53% | 5,914 |
| 30/04/24 | 129.2 | -2.17% | 25,355 |
End-of-day quote Pakistan S.E., May 05, 2024
More quotes
Otsuka Pakistan Limited is a Pakistan-based company engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods, and medical equipment. It is primarily focused on IV solutions and has a range of electrolyte solutions, carbohydrate solutions, and clinical nutrition products. Its products include intravenous solutions, medical devices, clinical nutrition, therapeutic drugs and nutraceutical products. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules, OTSUZOL, OTSUMOL infusion, and others. Its medical devices include urea breath test (UBT), Plasline solution, EUCATECH and Support C. Its clinical nutrition products include Aminoleban Oral, AMINOVEL 600, PAN-AMIN G, and AMINOLEBAN INJECTION. Its therapeutic drugs include Pletaal and Mucosta. Its nutraceutical products include ORTie, which is a special combination of dry salts and vitamin C to be mixed with safe water.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -7.25% | 5.64M | |
| +20.64% | 43.95B | |
| +22.22% | 22.49B | |
| +14.56% | 14.71B | |
| +10.88% | 13.77B | |
| +42.56% | 12.3B | |
| -8.70% | 7.03B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.75% | 5.48B |
- Stock Market
- Equities
- OTSU Stock
